VKTX
Viking Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$27.28Close
$3.1BMarket cap
$24.21 – $42.1352-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 22 · weaker than 78% of stocks over 12 months
- Far from its high 35% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
35%
1wk
up 11.8%
price change
1mo
down 16.3%
price change
12-month return
down 29%
market up 11% ·
its own down 33%
F-score
—
— Not assessed
Altman Z
22.11
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.9×
price / book
Earnings yield
down 13.3%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 47%
return on equity
Free cash margin
—
-$278.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.5%
$1.77 a day · 2×ATR $23.75
RS
22 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
0.71
50 sessions
Implied move
—
no scheduled report
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 2.9% over the year, from 112m to 115m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 28, 2026
Last shock
Sep 24, 2026-12% in one session8.0× volumeon an SEC filing-26% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$42.7M | -$55.7M | -$70.4M | -$100.8M | -$150.9M | -$393.3M |
| Net income | -$39.5M | -$55.0M | -$68.9M | -$85.9M | -$110.0M | -$359.6M |
| Earnings per share | — | -$0.71 | -$0.90 | -$0.91 | -$1.01 | -$3.19 |
| Free cash flow | -$21.8M | -$47.6M | -$48.4M | -$73.4M | -$87.8M | -$278.7M |
| Cash | $29.1M | $26.4M | $36.6M | $55.5M | $26.7M | $165.8M |
| Shareholders' equity | $244.3M | $201.9M | $145.3M | $348.4M | $880.3M | $639.1M |
| Shares outstanding | 73.22m | 78.25m | 78.26m | 100.11m | 111.57m | 114.79m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 29, 2026 | Quarterly ↗ | Jun 30, 2026 | 29d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 11, 2026 | Annual ↗ | Dec 31, 2025 | 42d |
| Oct 23, 2025 | Quarterly ↗ | Sep 30, 2025 | 23d |
| Jul 23, 2025 | Quarterly ↗ | Jun 30, 2025 | 23d |
| Apr 24, 2025 | Quarterly ↗ | Mar 31, 2025 | 24d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Oct 23, 2024 | Quarterly ↗ | Sep 30, 2024 | 23d |
| Jul 24, 2024 | Quarterly ↗ | Jun 30, 2024 | 24d |
| Apr 25, 2024 | Quarterly ↗ | Mar 31, 2024 | 25d |
| Feb 7, 2024 | Annual ↗ | Dec 31, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Results ↗ |
| Sep 28, 2026 | Material agreement · New obligation ↗ |
| Sep 22, 2026 | Other events ↗ |
| Jul 29, 2026 | Results ↗ |
| May 26, 2026 | Shareholder vote ↗ |
| Apr 29, 2026 | Results ↗ |
| Feb 11, 2026 | Results ↗ |
| Oct 22, 2025 | Results ↗ |
| Aug 19, 2025 | Regulation FD ↗ |
| Jul 23, 2025 | Results ↗ |
| May 27, 2025 | Shareholder vote ↗ |
| Apr 23, 2025 | Results ↗ |